August 10, 2022
July CPI inflation report is on tap before Wednesdays open.
Pre-open indications: 1 Sell into Strength, 3 Positive Indications, 4 Negative Indications and 1 Puff/Pump/Promote
RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
I DEVOTE a HUGE amount of time to “reckoning” the geography of my coverage group - it’s more than opinion, I deal in the facts and numbers that back them up.
The 8:00 A.M., ET edition
August 9, 2022
Upcoming Q2 earnings announcements … 29 of 35 reported so far
Agenus (AGEN),Avrobio (AVRO), Beam Therapeutics (BEAM), Caribou Biosciences (CRBU), Ionis Pharmaceuticals (IONS) and Verve Therapeutics (VERV) and Biolife Solutions (BLFS) reported Tuesday, 8/9
Brainstorm Cell Therapeutics (BCLI) on Monday, 8/15
Results are listed below ...
August 10, 2022
Pre-open indications: 6 HIT and 3 MISS
WHY and HOW is this market affecting the cell and gene therapy sector … “The Bottom Line” underlines the framework of share pricing actions.
Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?
No tunnel vision here, I get into the weeds of daily share pricing and causes
August 9, 2022
Upcoming Q2 earnings announcements … 29 of 35 reported so far Agenus (AGEN),Avrobio (AVRO), Beam Therapeutics (BEAM), Caribou Biosciences (CRBU), Ionis Pharmaceuticals (IONS) and Verve Therapeutics (VERV) and Biolife Solutions (BLFS) reported Tuesday, 8/9 Brainstorm Cell Therapeutics (BCLI) on Monday, 8/15 Results are listed below ...
July 21, 2022
VERV’s 8.3 M share offering has been priced at $27.00 with a -$6.01 or -16.74% drop in pre-market; Wednesday’s +$3.62, Tuesday’s +$5.98 and Monday’s +$2.60 following Friday’s -$0.49, Thursday’s -$0.97 and last Wednesday’s +$2.97 and the previous Tuesday’s +$1.72), J.P. Morgan, Jefferies, Guggenheim Securities and William Blair are acting as joint book-running managers for the offering.
July 13, 2022
Trading -$0.45 or -52.67% to $0.40 in the a.m. Closed down -$0.011 to $0.847 with an aftermarket of -$0.26 or -30.38% to $0.59 What a JOKE, actually a travesty for investors!
© 2022 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
